OIE Reference Laboratory Reports Activities

Transcription

1 OIE Reference Laboratory Reports Activities Activities in 2013 This report has been submitted : :27:05 Name of disease (or topic) for which you are a designated OIE Reference Laboratory: Transmissible gastroenteritis Address of laboratory: 1680 Madison Avenue Wooster, OH UNITED STATES OF AMERICA Tel.: Fax: address: saif.2@osu.edu website: Name (including Title) of Head of Laboratory (Responsible Official): Linda J. Saif, PhD Distinguished University Professor Name (including Title Position) of OIE Reference Expert: Linda J. Saif, PhD Distinguished University Professor Which of the following defines your laboratory? Check all that apply: Academic OIE Reference Laboratory Reports Activities,

2 ToR: To use, promote disseminate diagnostic methods validated according to OIE Stards 1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (t for quality control, proficiency testing or staff training) Diagnostic Test Indicated in OIE Manual (/) Total number of test performed last year Indirect diagnostic tests Nationally Internationally Antibody-ELISA 25 0 SN plaque reduction 20 0 Antigen ELISA 20 0 Direct diagnostic tests Nationally Internationally Cell culture immunofluorescence (ST cells) 20 0 RT-PCR nested PCR 60 5 ToR: To develop reference material in accordance with OIE requirements, implement promote the application of OIE Stards. To store distribute to national laboratories biological reference products any other reagents used in the diagnosis control of the designated pathogens or disease. 2. Did your laboratory produce or supply imported stard reference reagents officially recognised by the OIE? 3. Did your laboratory supply stard reference reagents (non OIE-approved) /or other diagnostic reagents to OIE Member Countries? 2 OIE Reference Laboratory Reports Activities, 2013

3 Type of reagent available Related diagnostic test Produced/ provide Amount supplied nationally (ml, mg) Amount supplied internationally (ml, mg). of recipient OIE Member Countries Region of recipients Control positive TGE virus viral RNA RT-PCR Produced various 500ul TGEV 4 Asia Pacific Middle East Control TGEV positive negative sera Ab-ELISA SN Produced various 1-2 ml amts 4 Asia Pacific Middle East Control positive TGE primers for RT-PCR RT-PCR Produced various 100ul TGEV RNA 1 Asia Pacific Middle East Control positive monoclonal antibody to TGEV Immunofluorescence, ELISA Produced 200ul 0 0 Asia Pacific Middle East 4. Did your laboratory produce vaccines? 5. Did your laboratory supply vaccines to OIE Member Countries? ToR: To develop, stardise validate, according to OIE Stards, new procedures for diagnosis control of the designated pathogens or diseases OIE Reference Laboratory Reports Activities,

4 6. Did your laboratory develop new diagnostic methods validated according to OIE Stards for the designated pathogen or disease? 7. Did your laboratory develop new vaccines according to OIE Stards for the designated pathogen or disease? Name of the new test or diagnostic method or vaccine developed Description References (Publication, website, etc.) TGEV/PRCV monoclonal antibody differential ELISA Simkins, R. A., P. A. Weilnau, J. Van Cott, T. Brim L. J. Saif Competition ELISA, using monoclonal antibodies to the TGEV S protein, for serologic differentiation of pigs infected with TGEV or porcine respiratory coronavirus. Am. J. Vet. Res. 54: Immunocytochemistry Shoup, D. I., D. E. Swayne, D. J. Jackwood L. J. Saif Immunocytochemistry of transmissible gastroenteritis virus antigens in fixed paraffin-embedded tissues. J. Vet. Diag. Invest. 8: TGEV/PRCV S-protein differential ELISA Sestak, K., Z. Zhou, D.I. Shoup L.J. Saif Evaluation of the baculovirus-expressed S glycoprotein of transmissible gastroenteritis virus (TGEV) as antigen in a competition ELISA to differentiate porcine respiratory coronavirus from TGEV antibodies in pigs. J. Vet. Diagn. Invest. 11: TGEV/PRCV differential RT-PCR Kim, L., K.O. Chang, K. Sestak, A. Parwani L.J. Saif Development of a reverse transcription-nested PCR assay for differential diagnosis of transmissible gastroenteritis virus (TGEV) porcine respiratory coronavirus (PRCV) from feces nasal swabs of infected pigs. J. Vet. Diagn. Invest. 12: N-protein-specific ELISA for TGEV vs SARS discrimination Vlasova, A., X. Zhang, M. Hasoksuz, N. Hadya L.J. Saif The two-way antigenic cross-reactivity between SARS-CoV group 1 animal CoVs is mediated through an antigenic site located in the N- terminal region of the SARS-CoV nucleoprotein. J. Virol. 81: ToR: To provide diagnostic testing facilities,, where appropriate, scientific technical advice on disease control measures to OIE Member Countries 8. Did your laboratory carry out diagnostic testing for other OIE Member Countries? Name of OIE Member Country seeking assistance Date (month). samples received for provision of diagnostic support. samples received for provision of confirmatory diagnoses ARGENTINA Jan 4 4 UNITED STATES OF AMERICA various OIE Reference Laboratory Reports Activities, 2013

5 9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country? Name of the OIE Member Country receiving a technical consultancy Purpose How the advice was provided ARGENTINA PT-PCR for TGEV/coronavirus diagnosis remote PERU PT-PCR for TGEV/coronavirus diagnosis remote CHINA (PEOPLE'S REP. OF) PT-PCR for TGEV/PEDV/coronavirus diagnosis vaccines in loco ToR: To carry out /or coordinate scientific technical studies in collaboration with other laboratories, centres or organisations 10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own? Title of the study Duration Purpose of the study Partners (Institutions) TGEV vaccine Develop test TGEV vaccines Dr Luis Enjuanes, CENTRO NACIONAL DE BIOTECNOLOGIA (CNB) SPANISH NATIONAL RESEARCH COUNCil Campus Universidad Autonoma Madrid, Spain TGEV/PEDV vaccines Diagnostics Develop test TGEV PEDV vaccines diagnostics Dr. Huabin Shao, Institute of Animal Husbry Veterinary Services, Ag Academy of Hubei Province, Wuhan, P.R. China TGEV/PEDV vaccines Diagnostics Develop test TGEV PEDV vaccines diagnostics Dr Li Feng, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China Animal coronavirus reference strains antisera Provide animal coronavirus reference reagents (deposited at ATTC) screen for animal coronaviruses or antibodies World Health Organization Animal coronavirus reference strains antisera Provide animal coronavirus reference reagents (deposited at ATTC) screen for animal coronaviruses or antibodies Dr. Malik Peiris OIE Reference Laboratory Reports Activities,

6 ToR: To collect, process, analyse, publish disseminate epizootiological data relevant to the designated pathogens or diseases 11. Did your Laboratory collect epizootiological data relevant to international disease control? 12. Did your laboratory disseminate epizootiological data that had been processed analysed? 13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category) a) Articles published in peer-reviewed journals: 3 Vlasova, A. L.J. Saif Biological Aspects of the Interspecies Transmission of Selected Coronaviruses. In: Viral Infections Global Change. (S.K. Singh, Ed.), John Wiley & Sons/Wiley Blackwell Press pages Hemida, M.G., R.A. Perera, P. Wang, M.A. Alhammadi, L.Y. Siu, M. Li, L.L. Poon,L.J. Saif, A. Alnaeem M. Peiris Middle East respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to Jung, K., Q. Wang, K.A. Scheuer, Z. Lu, Y. Zhang, L.J. Saif Pathology of US porcine epidemic diarrhea virus strain PC21A in gnotobiotic pigs. Emerg Infect Dis. b) International conferences: 3 Guest lecturer. Institute of Animal Husbry Veterinary Science, Agriculture Academy of Hubei province, Wuhan, P.R. China Int Vet Immunology Symposium, Milan, Italy International Congress on Pathogens at the Human-Animal Interface(ICOPHAI) Recife, Brazil c) National conferences: 2 Conference of Research Workers in Animal Diseases, Chicago, IL, National Institutes of Health, SARS MERS Coronaviruses d) Other: (Provide website address or link to appropriate information) 0 N/A ToR: To provide scientific technical training for personnel from OIE Member Countries To recommend the prescribed alternative tests or vaccines as OIE Stards 14. Did your laboratory provide scientific technical training to laboratory personnel from other OIE Member Countries? a) Technical visits: 0 b) Seminars: 1 c) Hs-on training courses: 2 d) Internships (>1 month): 2 6 OIE Reference Laboratory Reports Activities, 2013

7 Type of technical training provided (a, b, c or d) Country of origin of the expert(s) provided with training. participants from the corresponding country c,d Ethiopia 1 c,d Kenya 1 c,d China (Taipei) 1 b,c,d China (People's Republic) multiple ToR: To maintain a system of quality assurance, biosafety biosecurity relevant for the pathogen the disease concerned 15. Does your laboratory have a Quality Management System certified according to an International Stard? Explain Quality Management System in adoption process or currently in place Follows ASM,USDA NIH guidelines for work with cell cultures BSL 2 pathogens Follows ILACUC USDA requirements for animal care Follows NIH University guidelines for lab biosafety 16. Is your laboratory accredited by an international accreditation body? 17. Does your laboratory maintain a biorisk management system for the pathogen the disease concerned? (See Manual of Diagnostic Tests Vaccines for Terrestrial Animals 2012, Chapter or Manual of Diagnostic Tests for Aquatic Animals 2012, Chapter 1.1.1) ToR: To organise participate in scientific meetings on behalf of the OIE 18. Did your laboratory organise scientific meetings on behalf of the OIE? 19. Did your laboratory participate in scientific meetings on behalf of the OIE? OIE Reference Laboratory Reports Activities,

8 ToR: To establish maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease organise regular inter-laboratory proficiency testing to ensure comparability of results 20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease? t applicable (Only OIE Reference Lab. designated for disease) 21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests? t applicable (Only OIE Reference Lab. designated for disease) 22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest? t applicable (Only OIE Reference Lab. designated for disease) ToR: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens diseases to ensure equivalence of results 23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease? te: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: see point 1.3 Purpose for inter-laboratory test comparisons 1. participating laboratories Region(s) of participating OIE Member Countries Stardize RT-PCR for TGEV PEDV detection multiple state diagnostic labs Asia Pacific Middle East ToR: To place expert consultants at the disposal of the OIE 24. Did your laboratory place expert consultants at the disposal of the OIE? 8 OIE Reference Laboratory Reports Activities, 2013

9 Kind of consultancy Location Subject (facultative) Revisions for OIE Manual of Diagnostic Tests Vaccines for Terrestial Animals Paris Author revisions to Chapter OIE Terrestial Manual 25. Additional comments regarding your report: OIE Reference Laboratory Reports Activities,